logo
Scientists find Aleutian Range volcano offers clues to ‘stealthy' eruptions

Scientists find Aleutian Range volcano offers clues to ‘stealthy' eruptions

Yahoo6 days ago

Mount Veniaminof is pictured on July 8, 2024. A newly published study of the mountain increases knowledge of what are known as stealthy volcanoes, like Veniaminof. (Photo by Tara Shreve/Alaska Volcano Observatory/University of Alaska Fairbanks Geophysical Institute)
An ice-clad behemoth among Alaska's Aleutian Range mountains is sharing secrets about what makes some volcanoes tick — namely, ones that show little sign of erupting before they blow.
In a study published Tuesday in the journal Frontiers in Earth Science, scientists said they have discovered why Mount Veniaminof is so stealthy — and that information may help improve volcano forecasting and perhaps save lives.
Named after an 18th century Russian Orthodox priest, Veniaminof is what scientists call a 'stealthy volcano,' one that offers practically zero warning that an eruption is imminent. These volcanoes generally do not exhibit the typical precursors to eruptions, which may include rumbling, earthquakes, gas and steam plumes, and swollen or hot ground surfaces.
Stealthy volcanoes can be especially hazardous when located close to population centers. Merapi in Indonesia, Galeras in Colombia, Stromboli in Italy and Popocatépetl and Colima in Mexico are examples, according to the paper.
Unlike its more urban counterparts, Veniaminof sits in the remote Alaska Peninsula, some 480 miles southwest of Anchorage. The nearest village, Perryville, lies about 20 miles to the south. Perryville's population totaled 81 people at last count.
Veniaminof is one of Alaska's most active volcanoes, with 13 recorded eruptions since 1993, according to the study. Unlike Mount Redoubt, which triggered a near-disaster in 1989 when a jet bound for Anchorage lost engine power after flying into an ash cloud before recovering, or Mount Spurr, which coated Anchorage in ash and prompted airport closures during its 1992 eruption, Veniaminof's seismic activity has caused relatively little trouble for Alaska residents.
But its eruptions seem to come out of the blue. Of Veniaminof's 13 eruptions in the past three decades, only two produced warning signs, and a 2018 eruption went undetected until three days after it started.
The paper's lead author, Yuyu Li, a volcanology doctoral student at the University of Illinois Urbana-Champaign, found Veniaminof's behavior fascinating but disturbing. Given that the volcano can send ash nearly 10 miles into the atmosphere without warning, with the potential for disrupting air travel or posing other hazards, Li wanted to know more.
She and her team analyzed open-source monitoring data over three summer seasons immediately before the 2018 eruption. They created a model to understand what factors influence the likelihood of Veniaminof erupting. They considered several parameters, including magma flow rates, magma volumes and temperatures, and reservoir depths and shapes.
In a phone interview on Tuesday, Li said she and her colleagues found that a high flow of magma, or molten rock, into what's known as a chamber increases the chances of an eruption.
The volcano may not erupt. But if magma quickly fills the chamber and an eruption does occur, the ground will likely bulge or otherwise change shape, a process called deformation. That's something scientists would be able to detect.
They also found rapid movement of magma into a small chamber is likely to produce an eruption capable of being detected, not one without warning.
Stealthy eruptions occur more often when a low flow of magna enters a relatively small chamber, according to the research.
The study's results suggest that Veniaminof has a small magma chamber and a low flow of magma.
A chamber's size and shape factor heavily into the equation. Minimal earthquakes occur when magma enters larger, flatter chambers, according to the research.
Elongated chambers seem to produce less ground disturbance or deformation. If the rock is warm, it's less likely to crumble in ways that produce earthquakes.
Stealthy eruptions only occur when the precise conditions exist, involving the right magma flow and the right chamber size, depth and shape.
One of the paper's big takeaways is that volcanoes with small, warm reservoirs and slow magma flows are among those that ought to be most closely watched.
The biggest hazard from any eruption in Alaska is ashfall and disruption to aviation. Anything we can do to help predict that is important.
– Dave Schneider, acting scientist-in-charge, Alaska Volcano Observatory
Using the model created by Li and her colleagues and adding more instrumentation and real-time monitoring to stealthy volcanoes could help keep the public safer, Li said. It's a recipe for opening the door to improved volcano forecasting.
Dave Schneider, acting scientist-in-charge at the Alaska Volcano Observatory, didn't have a chance to read the full study on Tuesday. But from what he gleaned from the news release, he said AVO scientists will evaluate it and determine if any of the findings and recommendations should be implemented.
'The biggest hazard from any eruption in Alaska is ashfall and disruption to aviation,' said Schneider. 'Anything we can do to help predict that is important, given the constraints we have in terms of being able to get things in the ground and be able to interpret the data.'
Other stealthy volcanoes in Alaska include Cleveland, Shishaldin and Pavlov. The National Volcano Early Warning System lists them, as well as Veniaminof and others, as high priority in terms of their threat level.
Highest on the threat list are Akutan, Augustine, Makushin, Redoubt and Spurr.
Logistics and finances don't always allow for high-tech, costly instruments to be placed in as many spots as volcanologists would like or to the extent they would prefer to see.
'Resources are finite,' Schneider said.
Eruptions from stealthy volcanoes in Alaska also tend to be less explosive and life- and property-threatening than those from volcanoes offering ample warning signs, he said.
Right now, Spurr is by far more of an issue than Veniaminof for volcanologists. The volcano, located about 75 miles west of Anchorage, is currently in 'code yellow' status. That means low-level unrest is occurring with small earthquakes continuing beneath the surface and a weak steam plume arising from the top.
If magma were to move closer to the surface and other eruption indications were present, like ground deformation or increased hot gases and vapor plumes, the threat level would rise and scientists would advise the public that an eruption is very likely.
In March, scientists predicted that Spurr would erupt within weeks or months but the threat has since lessened.
SUPPORT: YOU MAKE OUR WORK POSSIBLE

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The unexpected ways Ozempic-like drugs might fight dementia
The unexpected ways Ozempic-like drugs might fight dementia

National Geographic

time11 hours ago

  • National Geographic

The unexpected ways Ozempic-like drugs might fight dementia

She can see the difference. Yazhou Li, a neuroscientist at the National Institute of Aging in Bethesda, Maryland, studies the effects of different drugs on brain impairments including traumatic brain injury, Alzheimer's disease, stroke, and Parkinson's disease. Working in the laboratory of neuroscientist Nigel Greig, Li and her colleagues test drugs on injured​ cells in dishes, run mice and rats through mazes, look at their brains. They are trying to find out if treatment with certain drugs might reduce the devastating effects of dementia or brain injury. And the latest drug they're testing? Seems to work. The damage is 'much more intense without treatment, and much more subdued with treatment,' Li says, though she cautions, 'the animals aren't, like, suddenly normal.' But after injury or in models of Alzheimer's or Parkinson's, mouse brains show less inflammation when the animals are given this drug. They move better and solve mazes faster than animals that don't receive the treatment. What's surprising is the drug in question. Li has been dosing the mice with one of the GLP-1 agonist drugs—the ​​suddenly-everywhere class of drugs that includes Ozempic, Wegovy, and Mounjaro. Originally designed to treat diabetes and help with weight loss, GLP-1 (glucagon-like peptide 1) agonists are being tested against a number of diseases as scientists explore their wide-ranging effects—and pharmaceutical companies look to make even more profits from the burgeoning wonder drugs. The drugs are currently in their silver bullet phase. No one doubts that they reduce insulin resistance, effectively treating ​t​​​ype 2 diabetes. But ​t​​ype 2 diabetes isn't just an insulin or blood sugar disease—it has many other possible effects. One of them: a higher risk of dementia as patients age. And as Li and a cohort of cognitive researchers are discovering, GLP-1 drugs might help reduce that risk. But how they work, how well they work, and who exactly will benefit from them are harder questions to answer. Diabetes and dementia Insulin is a vital molecule. After a person eats, beta cells in the pancreas release insulin into their blood. The hormone hits cells throughout the body, making them move glucose transporters to the cell membrane—opening the door for sugar to enter cells, which drives down glucose levels in the blood. The brain, however, ​​is a sugar hound​, using as much as 20 percent of ​​the glucose ​we produce. Glucose transporters are always present on brain cells, keeping the doors permanently open to sugar. But this doesn't mean insulin isn't important for our brain. In the brain, insulin is 'more of a growth factor,' says Christian Hölscher, a neuroscientist at the Henan Academy of ​Innovations in ​Medical Sciences and chief scientific officer at Kariya Pharmaceuticals, a drug company developing GLP-1 agonists to treat neurological diseases. It 'supports and drives gene expression linked to cellular growth, cellular repair, energy utilization.' In other words, it doesn't make cells take up sugar. Instead, it has another important task—helping to keep brain cells fully functional. This means if the brain becomes resistant to insulin—as it does with diabetes—the results can be catastrophic. 'Synapses [the connections between brain cells] burn through tons of glucose,' Hölscher explains, 'so if anything compromises that, then you will see the effects quite clearly.' Neurons will stop maintaining their synapses. 'Synapses stop working, and eventually they disappear, and then you're well on your way to Alzheimer or Parkinson's,' Hölscher says. A brain losing connections is a brain in distress, and inflammation abounds. 'There's inflammation in the brain with virtually every acute or long-term neurodegenerative disorder,' says Greig. Inflammation and insulin resistance in the brain are all linked to Alzheimer's disease, Parkinson's, and dementia. It's a connection that clinical neuroscientist Michal Schnaider Beeri has seen firsthand. The director of the Herbert and Jacqueline Krieger Klein Alzheimer's Research Center at Rutgers University in New Jersey has been following a large cohort of Israeli men for decades, looking at risk factors for issues like heart disease. As the years go by, she has seen something else: Those who developed ​t​ype 2 diabetes in midlife were nearly three times more likely to develop dementia. 'Diabetes, per se, is related to faster cognitive decline, mild cognitive impairment, and high dementia risk,' she says. Perhaps due to the drastically different roles of insulin in the body and the brain, insulin resistance in one doesn't always mean insulin resistance in the other. 'There are plenty of studies now that [show] in individuals with Alzheimer's disease, they have insulin resistance solely in their brain,' says Elizabeth Rhea, a neuroscientist at the University of Washington in Seattle. Which means they don't have ​​high blood sugar​, or require diabetes medicine. ​To make matters more complicated, insulin resistance in the brain isn't detectable with a blood test—it requires brain tissue, something that's basically impossible to get from live patients. For diabetics, the good news is that not everyone with insulin resistance in the body has to panic about their brains. But the difficulty of detecting brain insulin resistance also means that it can wreak havoc unnoticed for years, until the effects are severe enough to become apparent. ​ By then, it's often too late, says Natalie Rasgon, a neuroendocrinologist at the ​ Ichan ​ ​Icahn ​School of Medicine at Mount Sinai ​in New York City ​and director of the Center for Neuroscience in Women's Health at Stanford University. 'When you have a neurodegenerative disease, the train has left the station,' she says. 'You could try to mitigate the course [of the disease], but it's not a curable disease.' Saving at-risk neurons Scientists have known since the 1990s that insulin can improve the lives of cells affected by Alzheimer's disease, fighting against the clumps of insulin-blocking, synapse-clogging beta-amyloid that build up outside of diseased cells. More insulin could help the brain fight back. A few puffs of nasal insulin, it turns out, can improve memory in people with Alzheimer's, as well as in healthy older adults. 'Even with relatively short exposure times, just a few weeks, you could shift the needle on cognition or short-term memory and some biomarkers,' Hölscher says. The connection between improved insulin signals and cognition became visible in Schnaider Beeri's aging men. The researcher and her colleagues began to realize that brains with Alzheimer's looked different not only based on whether the patients had diabetes, but on whether they'd ever been treated for it. For patients who had been in treatment, their brains sometimes showed 'a little less' damage than the team expected. Schnaider Beeri's conclusion: 'Maybe the drugs for diabetes are doing something to [the] pathology of Alzheimer's.' Other scientists and drug companies were quickly coming to the same conclusion. Surveys across more than ​one ​million patients indicated that diabetics on metformin (Glucophage) and sodium-glucose cotransporter-2 inhibitors (drugs like Jardiance) developed dementia less frequently. Ozempic and the brain As much as GLP-1 agonists like Ozempic and Wegovy have gained cultural relevance as weight-loss drugs, they were originally approved to treat diabetes. The GLP-1 receptor in cell membranes binds hormones released after meals, stimulating the production of insulin. Drugs that activate the GLP-1 receptor, then, also promote insulin release. GLP-1 receptors are found in the brain, where they help brain cells grow and maintain their connections. And researchers like Greig, Li, and their colleagues have shown that the GLP-1 agonists do reduce brain injury in animal models ​​of​ stroke, traumatic brain injury, Parkinson's, Alzheimer's, and ALS. Meanwhile, when it comes to humans, Rasgon and her colleagues showed in 2019 that 12 weeks of liraglutide (Victoza)—another antidiabetic medication—improved connections between the memory-critical hippocampus and other brain regions, whether the participants were insulin resistant or not. ​Even better​, a 2020 Italian study showed that liraglutide could improve memory scores in diabetes patients. Schnaider Beeri is in the midst of a study funded by the Alzheimer's Association—due to end in 2027—that gives diabetic patients combinations of the GLP-1 agonist semaglutide (Ozempic, Wegovy), as well as intranasal insulin in older adults who are already cognitively impaired, to find out how well the treatments might rescue their brain function. Other scientists are pooling data from large cohorts—often from studies by pharmaceutical companies eager to find new markets for already popular drugs—to examine how many people who received GLP-1 agonists went on to develop dementia. In an Eli Lilly-funded study known as REWIND, dulaglutide (Trulicity) reduced mild cognitive impairment rates by 12 percent. In a study funded by Novo-Nordisk, the Dutch pharmaceutical company that manufactures Ozempic, people treated with GLP-1 agonists ended up with an 11 percent decrease in risk for dementia. 'I think it's good enough to keep looking,' says Christian Torp-Pederson, the cardiologist at Nordsjællands University Hospital in Denmark ​who ​​helped lead ​the study. Go slow, go steady, do studies With GLP-1 agonists already helping millions of people manage diabetes and weight loss, the added bonus of lowering the risk of dementia might seem like yet another reason to start taking one. But for otherwise healthy people, the science is not as clear-cut. First, the effect on cognition in nondiabetic brains might be too minor to matter. 'The majority of patients in the GLP-1 studies, they had a prior myocardial infarction or similar,' Torp-Pedersen says. 'So they were quite sick. And it is in this group we see a benefit.' And not every study even sees the same benefits, notes Riccardo De Giorgi, a psychiatrist at the University of Oxford in England. Some show differences in inflammation, others in cognition; some studies show no changes in cognitive function at all after treatment with a GLP-1. ​​​​ 'This topic has become so extremely popular, people obviously are getting quite excited,' De Giorgi says, adding, 'but sometimes that means doing things a bit quickly and maybe looking for a big, sensational title—a big message in the news, rather than doing some small, incremental, step science.' He is working on a study with a single injection of semaglutide in healthy patients. 'We are trying to establish whether these medications have any effects on…reward, impulsivity, emotional processing, memory and so on,' he says. Whether a particular drug has any effect will depend on if it gets into the brain at all, Rhea notes. The brain is protected by the blood-brain barrier—a thin layer of cells that carefully filters everything passing from the bloodstream to the brain. It has transporters for some molecules and allows others through—but many need not apply. Rhea and her colleagues have shown that while some GLP-1 agonists whoosh into the brain, others, like tirzepatide (Mounjaro, Zepbound), never cross at all. It's possible, she says, that for cognitive benefits, existing drugs might need to be tweaked to emphasize their effect on the brain versus the body. Of course, it would be helpful if scientists knew exactly how GLP-1 agonists were having an effect on dementia risk. Maybe insulin resistance is driving neurodegeneration, and GLP-1 agonists just make insulin signals better. 'I believe when these drugs are moving in the brain, insulin resistance is reversed, which in turn enhances cognition,' Rhea says. Others, like Greig and Li, think inflammation is the cause of cognitive decline. 'The inflammatory process in the brain is a double-edged sword,' Greig says. 'It's essential to be triggered for the healing process.' Immune cells in the brain turn on in response to injury. But they need to turn off or they'll do more harm than good. In neurodegenerative diseases, he says, the immune cells might be stuck in a pro-inflammatory state. It's possible GLP-1 agonists might quiet these cells, keeping them from damaging the very neurons they're meant to protect. Schnaider Beeri thinks damage to blood vessels in the brain could play a role. Insulin receptors sit on blood vessels. Insulin resistance could be 'impairing the vessel function. It could be impairing the vessel structure,' she explains. People with ​t​​ype 2 diabetes are also more susceptible to strokes and brain bleeds—which can in turn kill brain cells. As GLP-1 improves insulin signaling, the vessels could be able to function again. The answer to how GLP-1 agonists affect the brain could, of course, be all of the above. Insulin resistance could increase inflammation, which could impair blood vessels and eventually damage cells. Blood vessels could develop insulin resistance, cause cell damage, and inflammation could be the result. GLP-1 agonists could influence all of these processes. And while some GLP-1 drugs have been on the market for decades, scientists still aren't sure of the long-term effects, Rhea adds. It's far too soon to recommend that the average person start taking one as a hedge ​to ​protect their brains. 'That type of question appeared first with statins, you know, to lower cholesterol: 'Why don't we put statins in the drinking water?' We could put GLP-1s in the drinking water,' Torp-Pedersen says. But we don't put pharmaceuticals in the drinking water for good reason: 'We have yet to find a drug that's never dangerous.' GLP-1 agonists have plenty of unpleasant side effects: Nausea and constipation are common. ​​​​And those are the ones we know about. As more and more people take Ozempic, Wegovy, Zepbound, and the like, rare side effects—like pancreatitis or even sudden blindness—will probably become increasingly apparent. Even if it never makes sense for the average American to take GLP-1 agonists like they would take daily vitamins, the upside is considerable: An increasing body of research shows how these drugs might make a crucial impact in how we manage and mitigate the brutal effects of neurological disease. According to Alzheimer's Disease International, more than 55 million people were living with dementia in 2020—and that number will roughly double every 20 years. Having a drug on the shelf that might lessen the effects of an increasingly prevalent enemy would be a win-win. But there's still plenty of work to be done by ​​​​​lab scientists and clinicians alike​ before anyone can celebrate. This article is part of Your Memory, Rewired, a National Geographic exploration into the fuzzy, fascinating frontiers of memory science—including advice on how to make your own memory more powerful. Learn more.

Top AI researchers say language is limiting. Here's the new kind of model they are building instead.
Top AI researchers say language is limiting. Here's the new kind of model they are building instead.

Business Insider

time4 days ago

  • Business Insider

Top AI researchers say language is limiting. Here's the new kind of model they are building instead.

As OpenAI, Anthropic, and Big Tech invest billions in developing state-of-the-art large-language models, a small group of AI researchers is working on the next big thing. Computer scientists like Fei-Fei Li, the Stanford professor famous for inventing ImageNet, and Yann LeCun, Meta's chief AI scientist, are building what they call "world models." Unlike large-language models, which determine outputs based on statistical relationships between the words and phrases in their training data, world models predict events based on the mental constructs that humans make of the world around them. "Language doesn't exist in nature," Li said on a recent episode of Andreessen Horowitz's a16z podcast. "Humans," she said, "not only do we survive, live, and work, but we build civilization beyond language." Computer scientist and MIT professor, Jay Wright Forrester, in his 1971 paper "Counterintuitive Behavior of Social Systems," explained why mental models are crucial to human behavior: Each of us uses models constantly. Every person in private life and in business instinctively uses models for decision making. The mental images in one's head about one's surroundings are models. One's head does not contain real families, businesses, cities, governments, or countries. One uses selected concepts and relationships to represent real systems. A mental image is a model. All decisions are taken on the basis of models. All laws are passed on the basis of models. All executive actions are taken on the basis of models. The question is not to use or ignore models. The question is only a choice among alternative models. If AI is to meet or surpass human intelligence, then the researchers behind it believe it should be able to make mental models, too. Li has been working on this through World Labs, which she cofounded in 2024 with an initial backing of $230 million from venture firms like Andreessen Horowitz, New Enterprise Associates, and Radical Ventures. "We aim to lift AI models from the 2D plane of pixels to full 3D worlds — both virtual and real — endowing them with spatial intelligence as rich as our own," World Labs says on its website. Li said on the No Priors podcast that spatial intelligence is "the ability to understand, reason, interact, and generate 3D worlds," given that the world is fundamentally three-dimensional. Li said she sees applications for world models in creative fields, robotics, or any area that warrants infinite universes. Like Meta, Anduril, and other Silicon Valley heavyweights, that could mean advances in military applications by helping those on the battlefield better perceive their surroundings and anticipate their enemies' next moves. The challenge of building world models is the paucity of sufficient data. In contrast to language, which humans have refined and documented over centuries, spatial intelligence is less developed. "If I ask you to close your eyes right now and draw out or build a 3D model of the environment around you, it's not that easy," she said on the No Priors podcast. "We don't have that much capability to generate extremely complicated models till we get trained." To gather the data necessary for these models, "we require more and more sophisticated data engineering, data acquisition, data processing, and data synthesis," she said. That makes the challenge of building a believable world even greater. At Meta, chief AI scientist Yann LeCun has a small team dedicated to a similar project. The team uses video data to train models and runs simulations that abstract the videos at different levels. "The basic idea is that you don't predict at the pixel level. You train a system to run an abstract representation of the video so that you can make predictions in that abstract representation, and hopefully this representation will eliminate all the details that cannot be predicted," he said at the AI Action Summit in Paris earlier this year. That creates a simpler set of building blocks for mapping out trajectories for how the world will change at a particular time. LeCun, like Li, believes these models are the only way to create truly intelligent AI. "We need AI systems that can learn new tasks really quickly," he said recently at the National University of Singapore. "They need to understand the physical world — not just text and language but the real world — have some level of common sense, and abilities to reason and plan, have persistent memory — all the stuff that we expect from intelligent entities."

‘Forever chemicals' exposure before birth raises the risk of high blood pressure in teenage years
‘Forever chemicals' exposure before birth raises the risk of high blood pressure in teenage years

Yahoo

time5 days ago

  • Yahoo

‘Forever chemicals' exposure before birth raises the risk of high blood pressure in teenage years

'Forever chemicals' may be taking their toll on our health before we are even born, new research suggests. Per- and polyfluoroalkyl substances, or PFAS, are a group of chemicals used in everyday products like food packaging and non-stick cookware. They're known as 'forever chemicals' because they don't degrade easily and can build up in the environment – and in our bodies. Scientists have detected PFAS in people's blood, breast milk, semen, livers, and even brains. They suspect these chemicals harm human health, with studies linking them to higher cholesterol, some cancers, and fertility problems, among other issues. The new research adds another complication to that list: high blood pressure during adolescence. Related Forever chemicals: Brussels' mission to clean up Europe's water The analysis followed more than 1,000 children in the US. It used maternal plasma collected shortly after they were born to identify their level of prenatal PFAS exposure, and matched it to doctors' records up until their 18th birthdays. Prenatal exposure to PFAS was linked to a higher risk of developing high blood pressure later in childhood, particularly in the teenage years, according to the study published in the Journal of the American Heart Association. The findings indicate that 'these forever chemicals can have long-lasting and potentially harmful effects that may only become apparent years after birth,' Zeyu Li, the study's lead author and a researcher at Johns Hopkins University in the US, said in a statement. The risk of elevated blood pressure was even higher for boys and Black children with higher PFAS levels at birth, the study found. Related How 'dangerous chemicals' detected in products in the EU could be impacting your health In a surprise to researchers, a handful of forever chemicals were actually linked to lower diastolic, or bottom number, blood pressure in early childhood, though that changed when they entered their teenage years. Evidence on the health effects of PFAS has been mixed so far. While researchers believe these chemicals pose risks, it's difficult to pinpoint their exact impact because there are thousands of PFAS that could all interact in different ways, and because people's exposure changes over time. Even so, Li said the latest study underscores the need for researchers to track people's health and their PFAS levels over a long period of time, from early childhood to adolescence and beyond. Related How to avoid 'forever chemicals': 5 items you should stop using to minimise exposure to PFAS Meanwhile, Mingyu Zhang, the study's senior author and an assistant professor at Harvard Medical School, said stronger environmental protections are needed to protect people from PFAS, given they are so ubiquitous that people cannot meaningfully limit their exposure on their own. That could include phasing out forever chemicals from consumer products and in industrial settings, he said, as well as better surveillance and limits on PFAS in water systems. 'This is not something individuals can solve on their own,' Zhang said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store